912 related articles for article (PubMed ID: 12022710)
21. An overview on 5alpha-reductase inhibitors.
Aggarwal S; Thareja S; Verma A; Bhardwaj TR; Kumar M
Steroids; 2010 Feb; 75(2):109-53. PubMed ID: 19879888
[TBL] [Abstract][Full Text] [Related]
22. Role of 5α-reductase inhibitors in benign prostatic diseases.
Azzouni F; Mohler J
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):222-30. PubMed ID: 22333687
[TBL] [Abstract][Full Text] [Related]
23. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
Helfand BT; Blackwell RH; McVary KT
J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154
[TBL] [Abstract][Full Text] [Related]
24. Benign prostatic hyperplasia progression and its impact on treatment.
Djavan B; Waldert M; Ghawidel C; Marberger M
Curr Opin Urol; 2004 Jan; 14(1):45-50. PubMed ID: 15091050
[TBL] [Abstract][Full Text] [Related]
25. 5α-reductase type 3 enzyme in benign and malignant prostate.
Titus MA; Li Y; Kozyreva OG; Maher V; Godoy A; Smith GJ; Mohler JL
Prostate; 2014 Feb; 74(3):235-49. PubMed ID: 24150795
[TBL] [Abstract][Full Text] [Related]
26. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
Tarter TH; Vaughan ED
Curr Pharm Des; 2006; 12(7):775-83. PubMed ID: 16515494
[TBL] [Abstract][Full Text] [Related]
27. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
Botto H; Lan O; Poulain JE; Comenducci A
Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
[TBL] [Abstract][Full Text] [Related]
29. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
[TBL] [Abstract][Full Text] [Related]
30. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review.
Madersbacher S; Sampson N; Culig Z
Gerontology; 2019; 65(5):458-464. PubMed ID: 30943489
[TBL] [Abstract][Full Text] [Related]
31. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
32. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
[TBL] [Abstract][Full Text] [Related]
33. Current status of 5alpha-reductase inhibitors in the treatment of benign hyperplasia of prostate.
Kumar VL; Wahane VD
Indian J Med Sci; 2008 Apr; 62(4):167-75. PubMed ID: 18445985
[TBL] [Abstract][Full Text] [Related]
34. 5α-reductase type 1 modulates insulin sensitivity in men.
Upreti R; Hughes KA; Livingstone DE; Gray CD; Minns FC; Macfarlane DP; Marshall I; Stewart LH; Walker BR; Andrew R
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1397-406. PubMed ID: 24823464
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
36. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
[TBL] [Abstract][Full Text] [Related]
37. An update on the use of 5alpha-reductase inhibitors.
Foley CL; Bott SR; Shergill IS; Kirby RS
Drugs Today (Barc); 2004 Mar; 40(3):213-23. PubMed ID: 15148530
[TBL] [Abstract][Full Text] [Related]
38. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
Marberger M
Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone.
Dadras SS; Cai X; Abasolo I; Wang Z
Gene Expr; 2001; 9(4-5):183-94. PubMed ID: 11444528
[TBL] [Abstract][Full Text] [Related]
40. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
